What Candel Therapeutics, Inc. does.

We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. This is intended to lead to in-situ immunization against the injected tumor and uninjected distant metastases. Local administration is designed to achieve these therapeutic effects while minimizing systemic exposure and associated toxicity.

The immune cells induced by these viral immunotherapies are believed to target patients’ specific tumor antigens, potentially improving responses in immunologically “hot” tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed “cold” tumors with limited immune response into “hot” tumors. While our product candidates are administered directly into the tumor, we have observed systemic immune responses in our preclinical studies and clinical trials that may indicate the potential of our product candidates to induce systemic immune response against distal, uninjected tumors, also known as an “abscopal” effect.

Revenue and profit, by fiscal year.

More on CADL.

• Candel Therapeutics, Inc. summary
• Candel Therapeutics, Inc. financial statements
• Candel Therapeutics, Inc. key metrics
• Candel Therapeutics, Inc. health scores and style box
• Candel Therapeutics, Inc. earnings
• Candel Therapeutics, Inc. dividends
• Candel Therapeutics, Inc. valuation
• Candel Therapeutics, Inc. ownership and insiders
• Candel Therapeutics, Inc. peers

Figures from Candel Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.